If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles. With the S&P 500 trading at rich multiples and earnings expectations leaning heavily on tech, investors hunting for under-the-radar names near $50 a share have a reason to look ... If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket